TY - JOUR
T1 - Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma
AU - Abdallah, Al Ola
AU - Sigle, Monia
AU - Mohyuddin, Ghulam Rehman
AU - Coggins, Emily
AU - Remker, Cassie
AU - Shune, Leyla
AU - Mahmoudjafari, Zahra
AU - McGuirk, Joseph
AU - Ganguly, Siddhartha
N1 - Funding Information:
S.G. reports the following conflicts: speakers bureau for Seattle Genetics; research funding from Daiichi-Sankyo ; and honoraria and advisory board for Kite Pharma and Janssen. J.M. reports the following conflicts: research funding from Novartis , Fresenius Biotech , Astellas , Bellicum Pharmaceuticals , Gamida Cell , and Pluristem ; for Kite Pharmaceuticals, honoraria, advisory committee, research funding, and speakers bureau; and for Juno Therapeutics honoraria, advisory committee, and research funding. Z.M. reports advisory board for Genentech, Omeros, and Incyte. The other authors have stated that they have no conflict of interest.
Funding Information:
S.G. reports the following conflicts: speakers bureau for Seattle Genetics; research funding from Daiichi-Sankyo; and honoraria and advisory board for Kite Pharma and Janssen. J.M. reports the following conflicts: research funding from Novartis, Fresenius Biotech, Astellas, Bellicum Pharmaceuticals, Gamida Cell, and Pluristem; for Kite Pharmaceuticals, honoraria, advisory committee, research funding, and speakers bureau; and for Juno Therapeutics honoraria, advisory committee, and research funding. Z.M. reports advisory board for Genentech, Omeros, and Incyte. The other authors have stated that they have no conflict of interest.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/2
Y1 - 2021/2
N2 - Background: Aggressive relapsed/refractory multiple myeloma (RRMM) often requires salvage cytotoxic chemotherapy. We evaluated the efficacy and toxicity of VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) with an immunomodulatory agent (IMiD) in RRMM. Patients and Methods: We retrospectively reviewed the effectiveness and tolerability among 30 patients with RRMM receiving ≥ 1 cycle of VD-PACE + IMiD between January 2012 to April 2019. Results: Of 30 patients, 26 (86%) had myeloma double refractory to protease inhibitors and IMiDs, and had received a median of 3 lines prior of therapy. The overall response rate was 67.7%, 13% patients experienced complete remission or better, and 13% experienced very good partial response. Median progression-free and median overall survival were 11 and 26 months, respectively. The most common grade 3 or higher adverse events were hematologic events, which were manageable. Conclusion: VD-PACE + IMiD is an effective and tolerable salvage treatment for RRMM, with an impressive response rate in pretreated RRMM. The number of therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM) has increased significantly. We treated 30 patients with RRMM with VD-PACE + IMiD as salvage therapy followed by high-dose chemotherapy and autologous stem-cell transplantation. VD-PACE + IMiD is an effective and tolerable salvage treatment for RRMM, with an impressive response rate in pretreated RRMM.
AB - Background: Aggressive relapsed/refractory multiple myeloma (RRMM) often requires salvage cytotoxic chemotherapy. We evaluated the efficacy and toxicity of VD-PACE (bortezomib, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, etoposide) with an immunomodulatory agent (IMiD) in RRMM. Patients and Methods: We retrospectively reviewed the effectiveness and tolerability among 30 patients with RRMM receiving ≥ 1 cycle of VD-PACE + IMiD between January 2012 to April 2019. Results: Of 30 patients, 26 (86%) had myeloma double refractory to protease inhibitors and IMiDs, and had received a median of 3 lines prior of therapy. The overall response rate was 67.7%, 13% patients experienced complete remission or better, and 13% experienced very good partial response. Median progression-free and median overall survival were 11 and 26 months, respectively. The most common grade 3 or higher adverse events were hematologic events, which were manageable. Conclusion: VD-PACE + IMiD is an effective and tolerable salvage treatment for RRMM, with an impressive response rate in pretreated RRMM. The number of therapeutic options for patients with relapsed/refractory multiple myeloma (RRMM) has increased significantly. We treated 30 patients with RRMM with VD-PACE + IMiD as salvage therapy followed by high-dose chemotherapy and autologous stem-cell transplantation. VD-PACE + IMiD is an effective and tolerable salvage treatment for RRMM, with an impressive response rate in pretreated RRMM.
KW - Extramedullary disease
KW - High risk myeloma
KW - Plasmacytoma
KW - Relapsed myeloma
KW - Salvage therapy
UR - http://www.scopus.com/inward/record.url?scp=85092922533&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85092922533&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2020.09.002
DO - 10.1016/j.clml.2020.09.002
M3 - Article
C2 - 33093009
AN - SCOPUS:85092922533
SN - 2152-2650
VL - 21
SP - e220-e226
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 2
ER -